Discontinued — last reported Q2 '22
Dover Short-Term Borrowings decreased by 2.0% to $692.85M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 73.1%, from $400.26M to $692.85M. This is a positive signal — lower values indicate better performance for this metric.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $702.00K | $113.48M | $393.65M | $788.86M | $836.00K | $514.57M | $446.18M | $206.96M | $468.28M | $968.97M | $210.47M | $379.30M | $400.06M | $400.26M | $400.48M | $400.65M | $706.68M | $692.85M |
| QoQ Change | — | >999% | +246.9% | +100.4% | -99.9% | >999% | -13.3% | -53.6% | +126.3% | +106.9% | -78.3% | +80.2% | +5.5% | +0.1% | +0.1% | +0.0% | +76.4% | -2.0% |
| YoY Change | — | — | — | — | +19.1% | +353.4% | +13.3% | -73.8% | >999% | +88.3% | -52.8% | +83.3% | -14.6% | -58.7% | +90.3% | +5.6% | +76.6% | +73.1% |